These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 147978)

  • 1. Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release.
    Caine E; Kartzinel R; Ebert M; Carter AC
    Life Sci; 1978 Mar; 22(10):911-8. PubMed ID: 147978
    [No Abstract]   [Full Text] [Related]  

  • 2. Impaired prolactin release in Huntington's chorea. Evidence for dopaminergic excess.
    Hayden MR; Vinik AI; Paul M; Beighton P
    Lancet; 1977 Aug; 2(8035):423-6. PubMed ID: 70642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin secretion in Parkinson disease.
    Eisler T; Thorner MO; MacLeod RM; Kaiser DL; Calne DB
    Neurology; 1981 Oct; 31(10):1356-9. PubMed ID: 6810204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone and prolactin secretion in Huntington's disease.
    Levy CL; Carlson HE; Sowers JR; Goodlett RE; Tourtellotte WW; Hershman JM
    Life Sci; 1979 Feb; 24(8):743-9. PubMed ID: 155768
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of dopaminergic receptors in the regulation of growth hormone secretion.
    Müller EE; Liuzzi A; Cocchi D; Panerai AE; Oppizzi G; Lacatelli V; Mantegazza P; Silvestrini F; Chiodini PG
    Adv Biochem Psychopharmacol; 1977; 16():127-38. PubMed ID: 142419
    [No Abstract]   [Full Text] [Related]  

  • 6. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
    Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
    Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
    [No Abstract]   [Full Text] [Related]  

  • 7. Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea.
    Chalmers RJ; Johnson RH; Keogh HJ; Nanda RN
    J Neurol Neurosurg Psychiatry; 1978 Feb; 41(2):135-9. PubMed ID: 24678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone and prolactin secretion in liver cirrhosis: evidence for dopaminergic dysfunction.
    Borzio M; Caldara R; Ferrari C; Barbieri C; Borzio F; Romussi M
    Acta Endocrinol (Copenh); 1981 Aug; 97(4):441-7. PubMed ID: 7270004
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroendocrine evidence of normal hypothalamus-pituitary dopaminergic function in Huntington's disease.
    Markianos M; Panas M; Kalfakis N; Hatzimanolis J; Vassilopoulos D
    Neuro Endocrinol Lett; 2010; 31(3):359-62. PubMed ID: 20588235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian rhythmicity of prolactin secretion in Huntington's chorea.
    Polleri A; Savoldi F; Muratorio A; Masturzo P; Murialdo G; Martignoni E; Nappi G; Iudice A; Murri L
    Life Sci; 1980 May; 26(19):1609-17. PubMed ID: 6446012
    [No Abstract]   [Full Text] [Related]  

  • 11. [Huntington's chorea and somatotropic hormone: dynamic explorations in 27 cases (author's transl)].
    Destée A; Petit H; Fossati P; Warot P
    Rev Neurol (Paris); 1981; 137(1):21-31. PubMed ID: 6453416
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo and in vitro modulation of growth hormone and prolactin of a mixed somatotropic-lactotropic pituitary microadenoma.
    Muechler EK; Huang KE; McDonald JV; Tang L
    Am J Obstet Gynecol; 1987 Aug; 157(2):453-5. PubMed ID: 3113252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of dopaminergic pharmacological agents on thyrotropic hormone secretion by the hypophysis when stimulated with thyrotropin-releasing hormone].
    Boiadzhieva N; Zakharieva B; Ovcharov R
    Eksp Med Morfol; 1985; 24(1):29-32. PubMed ID: 3928331
    [No Abstract]   [Full Text] [Related]  

  • 14. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of dopamine agonists on human cardiovascular and sympathetic nervous systems.
    Ziegler MG; Kennedy B; Holland OB; Murphy D; Lake CR
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23(4):175-9. PubMed ID: 3158615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours.
    Jones MK; Ramsay ID; Jenner PG
    Br J Clin Pharmacol; 1978 May; 5(5):425-30. PubMed ID: 656281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington's disease.
    Durso R; Tamminga CA; Denaro A; Ruggeri S; Chase TN
    Neurology; 1983 Sep; 33(9):1229-32. PubMed ID: 6225034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin control in Huntington's chorea.
    Müller EE; Cocchi D; Mantegazza P; Parati EA; Caraceni T
    Lancet; 1977 Oct; 2(8041):764-5. PubMed ID: 71573
    [No Abstract]   [Full Text] [Related]  

  • 19. Central dopaminergic and serotoninergic systems in the regulation of adrenal tyrosine hydroxylase.
    Quik M; Sourkes TL
    J Neurochem; 1977 Jan; 28(1):137-47. PubMed ID: 13151
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of dopaminergic drugs on pituitary hormone release in normal subjects.
    Sekso M; Solter M; Banovac K; Vizner B; Petek M
    Acta Med Iugosl; 1977; 31(4):321-32. PubMed ID: 596235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.